Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China

Oct 15, 2019 21:24 JST

Source: Eisai

TOKYO, Oct 15, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. Fycompa was designated for Priority Review by the NMPA due to its significant clinical benefits compared to existing treatments, and was approved in about 12 months since the submission in September 2018.

In China, it is estimated that there are approximately 9 million patients with epilepsy, approximately 60% of whom being affected by partial-onset seizures. About 40% patients with partial-onset seizures require adjunctive treatment.1 As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs,2 this is a disease with significant unmet medical needs.

Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. Administered orally once-daily, it is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes.

Fycompa has been approved in over 60 countries around the world as an adjunctive treatment for partial- onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older. In addition, Fycompa has been approved in over 55 countries as an adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In the United States, Fycompa is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older.

Eisai considers neurology including epilepsy, a therapeutic area of focus. With this approval of Fycompa in China, Eisai pursues our mission to provide "seizure freedom" to a greater number of patients with epilepsy across the world living. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

Contact:

Eisai Co., Ltd. 
Public Relations Department
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Related Press Release

FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

January 26 2026 10:37 JST

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time

January 21 2026 15:44 JST

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan

January 13 2026 08:50 JST

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

January 06 2026 09:43 JST

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

December 11 2025 18:41 JST

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

December 09 2025 17:51 JST

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

December 04 2025 17:36 JST

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

December 03 2025 17:19 JST

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

December 02 2025 23:01 JST

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan

November 28 2025 22:00 JST

More Press release >>

Latest Press Release

Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 02, 2026 16:29 JST

Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 02, 2026 14:30 JST

JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 02, 2026 10:00 JST

NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST

ANIME TOKYO STATION ON ROBLOX: Commemorating the One-Year Anniversary with Gifts and a Wealth of Add-on Content
Jan 30, 2026 09:00 JST

MAZDA CX-5 Achieves Five Million Units in Global Production and Sales
Jan 29, 2026 16:15 JST

The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment
Jan 29, 2026 12:00 JST

Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
Jan 29, 2026 10:14 JST

TANAKA Recognized as a "Tokyo Sports Promotion Company" for the 11th Consecutive Year
Jan 28, 2026 22:00 JST

NTT, DOCOMO, and NTT DATA to Exhibit at MWC Barcelona 2026
Jan 28, 2026 18:29 JST

MHI Thermal Systems Receives "Minister of Economy, Trade and Industry Award" and MHI's Aerospace Parts Factory Receives "Agency for Natural Resources and Energy Commissioner's Award" at 2025 Energy Conservation Grand Prize Awards
Jan 28, 2026 18:08 JST

Mitsubishi Power Completes GTCC Upgraded Reliability Package at VPI's Damhead Creek Power Station
Jan 28, 2026 17:58 JST

Fujitsu and Tokai National Higher Education and Research System develop space weather prediction capabilities technology leveraging AI
Jan 28, 2026 10:55 JST

NEC Develops High-Efficiency, Compact Power Amplifier Module for 5G Base Station Radio Units
Jan 28, 2026 10:05 JST

Shoucheng Holdings-Backed Robotics Firms Set to Appear at 2026 CMG New Year's Gala
Jan 28, 2026 09:35 JST

The 19th Asian Financial Forum concludes successfully
Jan 27, 2026 23:27 JST

NTT DOCOMO Develops a Solution to Streamline DOOH Advertiser Review Operations
Jan 27, 2026 10:25 JST

Fujitsu launches new platform enabling autonomous operation of generative AI optimized for in-house applications in a dedicated environment
Jan 26, 2026 13:30 JST

Mitsubishi Heavy Industries and Mitsubishi Electric Invest in Japan LEO Shachu, a Space Venture Established by Mitsui & Co.
Jan 26, 2026 13:24 JST

CaoCao Inc. Ushers in China's Fully Purpose-Built Robotaxi Era, Aims to Deploy 100,000 Robotaxis by 2030
Jan 26, 2026 11:51 JST

More Latest Release >>